Drugs / HyperAcute® Melanoma vaccine
last change Jun 2011 re-read 2 minutes ago

HyperAcute® Melanoma vaccine

also known as HyperAcute-Melanoma

Vaccine

Developed for
melanoma
Investigated by
NewLink Genetics Corporation · Ochsner Health System

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00746746 Jun 2008 → Jun 2010 melanoma Ochsner Health System Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HyperAcute Melanoma vaccine “The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine” NCT00746746
Known as HyperAcute-Melanoma “The study vaccine (HyperAcute®-Melanoma) is made from three types of human melanoma cell lines” NCT00746746
Modality Vaccine “HyperAcute® Melanoma vaccineNCT00746746